venetoclax,rituximab,bendamustine
roche,abbvie
['murano', 'lymsm', 'cll']
#eha2023 | arnon kater shares the final 7-year follow up data from the murano trial of venr in r/rcll. os 69.6% and 51% in venr and br treated pts, respectively. pfs 23% venr and 0% br. median pfs 23.3mo in venr-retreated pts. #cll #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm